Targeting the Akt/mTOR pathway in Brca1-deficient cancers

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

(2014) Terence O'Reilly et al.   Translational Oncology

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

(2009) R Diaz et al.   BRITISH JOURNAL OF CANCER

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers

(2009) P van der Groep et al.   JOURNAL OF CLINICAL PATHOLOGY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer

(2008) Kirsimari Aaltonen et al.   BREAST CANCER RESEARCH AND TREATMENT

Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability

(2008) Q. Xue et al.   CANCER RESEARCH

Negative Regulation of AKT Activation by BRCA1

(2008) T. Xiang et al.   CANCER RESEARCH